{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["acalabrutinib"]],"indication":"previously untreated diffuse large B-cell lymphoma","name":"REMoDL-A","nct_id":"NCT04546620","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=remodl-a-nct04546620. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"REMoDL-A","arms":[{"description":"6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy every 21 days.","label":"Arm A Control","type":"ACTIVE_COMPARATOR"},{"description":"1 cycle of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy followed by 5 cycles of R-CHOP + acalabrutinib taken twice daily for 21 day cycles.","label":"Arm B Experimental","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2028-05","type":"ESTIMATED"},"conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":{"count":453,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"R-CHOP","otherNames":["Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisolone"],"type":"DRUG"},{"name":"R-CHOP + acalabrutinib","otherNames":["Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisolone","Acalabrutinib"],"type":"DRUG"}],"last_update":"2026-04-30","lead_sponsor":"University Hospital Southampton NHS Foundation Trust","official_title":"A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma With Acalabrutinib","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To establish if combining acalabrutinib with R-CHOP improves efficacy, compared to RCHOP alone, for the treatment of previously untreated patients with DLBCL to a degree that justifies further development of this approach.","timeFrame":"Last patient's last follow up, approximately 4.5 years. Patients who do not experience a PFS event will be censored at the date of last follow up."}],"references":[],"start_date":{"date":"2021-10-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)","url":"https://clinicaltrials.gov/study/NCT04546620"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/remodl-a-nct04546620"}